Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Berberine (CAS 2086-83-1): AMPK Activator and NLRP3 Modul...

    2025-10-26

    Berberine (CAS 2086-83-1): AMPK Activator and NLRP3 Modulator for Metabolic & Inflammation Research

    Executive Summary: Berberine (CAS 2086-83-1) is an isoquinoline alkaloid isolated from Cortex Phellodendri Chinensis, exhibiting a molecular weight of 336.36 and a chemical formula of C20H18NO4 (ApexBio). It activates AMP-activated protein kinase (AMPK), leading to improved glucose and lipid metabolism in cellular and animal models (Li et al., 2025). Berberine upregulates hepatic LDL receptor (LDLR) expression and inhibits NLRP3 inflammasome-mediated inflammation. It shows potent, dose-dependent effects in human hepatoma cells and hyperlipidemic rodent models. Its workflow parameters require strict solubility and storage conditions for optimal reproducibility (ApexBio Data Sheet).

    Biological Rationale

    Berberine is classified as an isoquinoline alkaloid, primarily sourced from Cortex Phellodendri Chinensis (ApexBio). This compound has a long history in metabolic disease research due to its dual action as an AMPK activator and inflammation modulator (MoleculeProbe, 2023). Chronic metabolic conditions such as diabetes, obesity, and cardiovascular disease are characterized by aberrant glucose/lipid homeostasis and persistent inflammation. The NLRP3 inflammasome has emerged as a central node in these processes, linking metabolic perturbations to cytokine production and cell death. By targeting both AMPK and NLRP3, Berberine addresses key drivers of metabolic dysfunction and immune activation (Li et al., 2025).

    Mechanism of Action of Berberine (CAS 2086-83-1)

    Berberine exerts its primary effects via two convergent pathways:

    • AMPK Activation: Berberine directly activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. AMPK activation leads to inhibition of hepatic gluconeogenesis and increased fatty acid oxidation. This pathway is critical for improving insulin sensitivity and lowering blood glucose in metabolic models (GW9508.com).
    • LDLR Upregulation: In human hepatoma cell lines (HepG2, Bel-7402), Berberine upregulates low-density lipoprotein receptor (LDLR) mRNA and protein expression in a dose-dependent manner, with maximal induction at 15 μg/mL. Increased LDLR enhances hepatic clearance of LDL cholesterol (ApexBio).
    • NLRP3 Inflammasome Modulation: Berberine inhibits the NLRP3 inflammasome, a key mediator of sterile inflammation and pyroptotic cell death. This action reduces IL-1β and IL-18 cytokine production in response to danger-associated molecular patterns (DAMPs) such as oxidized self-DNA (Li et al., 2025).

    This mechanistic profile extends and updates insights from prior reviews by integrating both metabolic and innate immune axes (AktAntibody.com).

    Evidence & Benchmarks

    • Berberine upregulates LDLR mRNA and protein in HepG2 and Bel-7402 cells in a dose-dependent manner, with maximal effects at 15 μg/mL (ApexBio, product page).
    • In hyperlipidemic female golden hamsters, oral Berberine at 50 or 100 mg/kg/day for 10 days reduces serum total and LDL cholesterol, correlating with hepatic LDLR induction (ApexBio, product page).
    • AMPK activation by Berberine leads to metabolic reprogramming and improved glucose/lipid handling in multiple preclinical models (MoleculeProbe, 2023).
    • Berberine suppresses NLRP3 inflammasome-mediated pyroptosis and attenuates inflammation in acute kidney injury models (Li et al., 2025).
    • Berberine is insoluble in water and ethanol, but dissolves at ≥14.95 mg/mL in DMSO with warming (37°C) or sonication (ApexBio, product page).

    Applications, Limits & Misconceptions

    Berberine is extensively used as a reference compound in research models of diabetes, obesity, and cardiovascular disease. Its dual action on metabolism and inflammation enables its application in acute kidney injury and systemic inflammatory response models (Adrenomedullin.us). By integrating cGAS-STING/NLRP3 axis insights, this article clarifies Berberine’s unique translational position over standard AMPK activators alone. For a systems pharmacology perspective, see this review, which focuses on whole-organism integration, whereas this article provides experimental detail and workflow guidance.

    Common Pitfalls or Misconceptions

    • Limited Water/Ethanol Solubility: Berberine is insoluble in water and ethanol; improper solvent choice can confound in vitro results (ApexBio).
    • Not a Universal Anti-Inflammatory: Berberine’s NLRP3 inhibition is context-dependent and does not block all inflammatory pathways.
    • Clinical Translation Requires Caution: Doses effective in rodent models may not directly translate to human dosing or outcomes.
    • Stability Issues: Berberine solutions degrade with prolonged storage; fresh preparation is recommended for reproducibility.
    • Not Suitable as a Monotherapy: Berberine is best used as a research tool or adjunct, not a standalone clinical agent.

    Workflow Integration & Parameters

    Solubility and Storage: Berberine should be dissolved at ≥14.95 mg/mL in DMSO, with gentle warming to 37°C or ultrasonic agitation. Long-term solutions are unstable; aliquots must be stored at -20°C, sealed, and protected from moisture/heat. Use stock solutions promptly (ApexBio).

    Experimental Models: In vitro, treat HepG2 or Bel-7402 cells with 5–15 μg/mL for 24–48 hours to assess LDLR induction. In vivo, administer 50–100 mg/kg/day orally in rodent models for 10 days to evaluate lipid-lowering and inflammation endpoints.

    Assay Recommendations: Include controls for solvent (DMSO), vehicle, and consider measuring AMPK phosphorylation and IL-1β/IL-18 release for mechanistic validation.

    Conclusion & Outlook

    Berberine (CAS 2086-83-1) provides a unique platform for dissecting metabolic and innate immune mechanisms in preclinical research. Its validated dual action on AMPK and NLRP3 sets it apart from single-pathway modulators. Careful attention to solubility, dosing, and stability is essential for robust results. For those seeking to benchmark or extend Berberine’s utility in metabolic and inflammation research, the N1368 kit offers standardized quality and documentation. This article clarifies workflow boundaries and extends earlier reviews by integrating new inflammasome biology and translational guidance.